Drug Discovery News and Research

RSS

The drug discovery process begins with recognizing a disease or clinical condition in which there is a lack of adequate medical treatment. Once a potential drug has been identified, pre-clinical research can begin. This process includes several stages; the first of which involves identifying and validating the prospective drug’s target through assay development, high throughput screening, hit identification and finally, lead optimization. Once the pre-clinical process is complete, the newly synthesized drug candidate is selected for future clinical development.

Experimental compound reduces cell death, inflammation, and organ damage in diabetes

An experimental compound reduced the cell death, inflammation, and organ damage seen with diabetes.

29 Oct 2025

Scripps Research wins $4 million CIRM grant to develop novel platform for neurodevelopmental disorders

Most people are born with two functioning copies of each gene-one inherited from each parent. In many cases, having just one working copy is enough for the body to function normally.

28 Oct 2025

Scientists uncover excessive maturation and aging in the hippocampus

In a groundbreaking study, researchers at Fujita Health University and the Tokyo Metropolitan Institute of Medical Science have uncovered a previously overlooked form of brain abnormality linked to anxiety: excessive maturation and aging in the hippocampus, a state they term "hyper-maturity."

27 Oct 2025

Researchers uncover and inhibit a key cell death pathway in severe cutaneous adverse reactions

A collaborative research group led by Haruna Kimura (graduate student), Dr. Akito Hasegawa (Assistant Professor), and Prof. Riichiro Abe from the Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, together with Prof. Takemasa Ozawa from the Department of Chemistry, School of Science, The University of Tokyo, and Dr. Yoichi Ogawa (Lecturer) from the Department of Dermatology, Faculty of Medicine, University of Yamanashi, has developed a novel therapeutic candidate that may improve the prognosis of severe cutaneous adverse reactions such as Stevens–Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN).

24 Oct 2025

Les Turner Symposium on ALS brings researchers and clinicians to discuss new research findings

The 15th annual Les Turner Symposium on ALS will be held on Monday, Nov. 3, 2025 in Chicago. Hosted by the Les Turner ALS Foundation and the Les Turner ALS Center at Northwestern Medicine, this event will gather leading ALS researchers and clinicians to discuss the latest research and perspectives on the disease.

23 Oct 2025

GemPharmatech collaborates with MSK Cancer Center to accelerate discovery of therapeutic antibodies

GemPharmatech, a global leader in preclinical research solutions and genetically-engineered mouse models, today announced a collaboration with Memorial Sloan Kettering Cancer Center (MSK) to accelerate the discovery of new therapeutic antibodies.

23 Oct 2025

Enamine contributes to the discovery of promising broad-spectrum coronavirus antiviral

Enamine, a leading chemistry and R&D services company, today announced that it was a key synthetic chemistry contributor to a first-of-its-kind, open-science approach that led to the development of a promising broad-spectrum coronavirus antiviral pre-clinical candidate.

23 Oct 2025

How psychedelics profoundly reshape the perception of time and consciousness

A perspective article published in Psychedelics by Prof. Xiaohui Wang and colleagues examines how psychedelic substances profoundly reshape the perception of time, offering unprecedented insights into consciousness and potential therapeutic applications.

23 Oct 2025

Giles introduces AI agent to accelerate healthcare and life science research

giles AI, a company making advanced research tools accessible to all and simplifying how scientists work with data, has announced the commercial launch of giles, its AI specialised research agent designed to support healthcare, clinical, and medical research.

21 Oct 2025

Cyclana Bio raises £5M to advance drug discovery for endometriosis

Cyclana Bio, a biotechnology company pioneering tissue-level approaches to women's health, today announced the close of a £5M pre-seed funding round, co-led by NfX and Eka VC, and including Cocoa VC, Wilbe, and Angel investors.

21 Oct 2025

VICT3R project builds momentum to accelerate animal-free safety testing

The VICT3R project is expanding its consortium by adding new beneficiaries and organisations to the network of contract research organisations (CROs) associated with the project.

16 Oct 2025

AI predicts cell responses to drugs and genetic changes

Controlling the state of a cell in a desired direction is one of the central challenges in life sciences, including drug development, cancer treatment, and regenerative medicine.

16 Oct 2025

LassoESM accelerates discovery of therapeutic peptides

In the hunt for new therapeutics for cancer and infectious diseases, lasso peptides prove to be a catch.

16 Oct 2025

Machine learning advances drug discovery through generalizable models

The drug development pipeline is a costly and lengthy process. Identifying high-quality "hit" compounds-those with high potency, selectivity, and favorable metabolic properties-at the earliest stages is important for reducing cost and accelerating the path to clinical trials.

16 Oct 2025

UC Irvine develops human-like colon model for precision medicine

Researchers at the University of California, Irvine have developed a 3D human colon model integrated with bioelectronics to aid in colorectal cancer research and drug discovery.

15 Oct 2025

New insights into MDMA therapy for PTSD and beyond

A comprehensive peer-reviewed invited review published today in Psychedelics by Dr. Kenji Hashimoto and colleagues (Dr. Mingming Zhao and Dr. Jianjun Yang) synthesizes the evolving landscape of MDMA-assisted psychotherapy, examining robust clinical evidence in treatment-resistant posttraumatic stress disorder while identifying promising applications in autism spectrum disorder, eating disorders, and existential distress

14 Oct 2025

CN Bio launches all-in-one Organ-on-a-chip system

CN Bio, a leading provider of benchtop Organ-on-a-chip (OOC) solutions that accelerate drug discovery and development, today announced the launch of PhysioMimix® Core.

14 Oct 2025

New AI system revolutionizes drug design and vaccine development

The rapid advancement of artificial intelligence (AI) is transforming the field of structural biology. In May 2024, DeepMind and Isomorphic Labs launched AlphaFold 3 (AF3), a revolutionary AI system capable of predicting the 3D structures and interactions of proteins, nucleic acids, small molecules, ions, and other biomolecules with remarkable precision.

10 Oct 2025

Discovery of vascular-associated fibroblastic cells opens new path for diabetes treatment

Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks the cells that produce insulin-a critical hormone that regulates blood sugar in the body.

8 Oct 2025

COMBINEDBrain and MUSC join forces to launch pediatric CNS biorepository

COMBINEDBrain, a leader in advancing translational neuroscience research, and the Medical University of South Carolina (MUSC), one of the nation's premier academic health centers, are excited to announce a strategic partnership to establish a cutting-edge biorepository for pediatric central nervous system (CNS) tissue and biofluids.

7 Oct 2025